NCT06686030

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Akeso · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)

Detailed description

This is a Phase 2, open label, multicohort, multicenter study designed to evaluate the efficacy and safety of combination of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer. AK112 is a bispecific monoclonal antibody targeting VEGF and PD-1.

Conditions

• Platinum-sensitive Ovarian Cancer

Interventions

Type	Name	Description
DRUG	AK112 low dose	10mg/kg, Q3W, ivgtt
DRUG	Chemotherapy	ivgtt
DRUG	Olaparib	bid, oral
DRUG	AK112 high dose	20mg/kg, Q3W, ivgtt

Timeline

• Start date: 2025-02-17
• Primary completion: 2027-10-01
• Completion: 2028-07-01
• First posted: 2024-11-13
• Last updated: 2025-04-16

Locations

1 site across 1 country: China